ESC 365 - When should we add PCSK-9 inhibitors?

ESC Premium Access

When should we add PCSK-9 inhibitors?

Session: Lipid-lowering therapy: how to tailor treatment to your patient

Topic: Risk Factors and Prevention

Speaker: Professor S. Nicholls (Melbourne, AU)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Stephen Nicholls

Monash University, Melbourne (Australia)

53 presentations

5 followers

3 more presentations in this session

Treatment intensity in primary and secondary prevention? The role of precision medicine.

Speaker: Professor J. Deanfield (London, GB)

Should we address other lipid/lipoproteins besides LDL-C?

Speaker: Professor R. Frikke-Schmidt (Copenhagen, DK)

Is there a place for anti-inflammatory medication in clinical practice?

Speaker: Professor K. Ray (London, GB)

Access the full session

Lipid-lowering therapy: how to tailor treatment to your patient

Speakers: Professor S. Nicholls, Professor J. Deanfield, Professor R. Frikke-Schmidt, Professor K. Ray

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources